Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults

Oral ANAVEX^®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing

Read more at globenewswire.com